Ikarian Capital, LLC Immunovant, Inc. Put Options Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $4.98 Million - $7.03 Million	159,166 Added 2876.15%	164,700 $6.94 Million
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $1.31 Million - $2.82 Million	-70,466 Reduced 92.72%	5,534 $212,000
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $1.08 Million - $1.81 Million	76,000 New	76,000 $1.44 Million
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $1.74 Million - $3.12 Million	-185,100 Reduced 76.24%	57,700 $610,000
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $3.18 Million - $12 Million	242,800 New	242,800 $3.9 Million

238

62.9M

1.46M

546K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.